Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Social media 'high priority' for FDA 2012, despite lack of 2012 guidance

This article was originally published in Scrip

Executive Summary

The list of new and revised guidelines that the US Food and Drug Administration is planning to publish in 2012 makes no mention of its long-awaited guidance on promotion of prescription drugs using social media tools. However, the agency has confirmed to Scrip's sister publication, Scrip Regulatory Affairs, that it has not put this topic on the backburner and that "policy and guidance development for promotion of FDA-regulated medical products using the Internet and social media tools are among our highest priorities".

You may also be interested in...



EMA Aims For Better Info On Benefit-Risk Balance To Support Drug Choices In Pregnancy

The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.

Study Shows RWD Can Replace Placebo Data In Duchenne Trials

A first-of-its-kind collaborative study has found that real-world and natural history data are comparable to placebo data from clinical trials in Duchenne muscular dystrophy.

EU Panel Sets Ambitious Big Data Workplan

An EU group has listed several ambitious projects to help EU regulators realize their cherished vision of using big data capabilities to support innovation and public health. But these proposals may take a backseat as COVID-19-related challenges continue.

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel